Conceptual design of a universal donor screening approach for vaginal microbiota transplant

Kevin Delong, Sabrine Bensouda, Fareeha Zulfiqar, Hannah C. Zierden, Thuy M. Hoang, Alison G. Abraham, Jenell S. Coleman, Richard A. Cone, Patti E. Gravitt, Craig W. Hendrix, Edward J. Fuchs, Charlotte A. Gaydos, Ethel D. Weld, Laura M. Ensign

Research output: Contribution to journalArticle

Abstract

The success of fecal microbiota transplant (FMT) in treating recurrent Clostridioides difficile infection has led to growing excitement about the potential of using transplanted human material as a therapy for a wide range of diseases and conditions related to microbial dysbiosis. We anticipate that the next frontier of microbiota transplantation will be vaginal microbiota transplant (VMT). The composition of the vaginal microbiota has broad impact on sexual and reproductive health. The vaginal microbiota in the “optimal” state are one of the simplest communities, dominated by one of only a few species of Lactobacillus. Diversity in the microbiota and the concomitant depletion of lactobacilli, a condition referred to as bacterial vaginosis (BV), is associated with a wide range of deleterious effects, including increased risk of acquiring sexually transmitted infections and increased likelihood of having a preterm birth. However, we have very few treatment options available, and none of them curative or restorative, for “resetting” the vaginal microbiota to a more protective state. In order to test the hypothesis that VMT may be a more effective treatment option, we must first determine how to screen donors to find those with minimal risk of pathogen transmission and “optimal” vaginal microbiota for transplant. Here, we describe a universal donor screening approach that was implemented in a small pilot study of 20 women. We further characterized key physicochemical properties of donor cervicovaginal secretions (CVS) and the corresponding composition of the vaginal microbiota to delineate criteria for inclusion/exclusion. We anticipate that the framework described here will help accelerate clinical studies of VMT.

Original languageEnglish (US)
Article number306
JournalFrontiers in Cellular and Infection Microbiology
Volume9
Issue numberAUG
DOIs
StatePublished - Jan 1 2019

Fingerprint

Donor Selection
Microbiota
Transplants
Reproductive Health
Lactobacillus
Dysbiosis
Tissue Donors
Bacterial Vaginosis
Infectious Disease Transmission
Premature Birth
Sexually Transmitted Diseases
Therapeutics
Transplantation

Keywords

  • Bacterial vaginosis (BV)
  • Cervicovaginal secretions (CVS)
  • Fecal microbiota transplant (FMT)
  • Lactobacillus
  • Microbiota
  • Sexually transmitted infections
  • Urinary tract infection (UTI)

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Conceptual design of a universal donor screening approach for vaginal microbiota transplant. / Delong, Kevin; Bensouda, Sabrine; Zulfiqar, Fareeha; Zierden, Hannah C.; Hoang, Thuy M.; Abraham, Alison G.; Coleman, Jenell S.; Cone, Richard A.; Gravitt, Patti E.; Hendrix, Craig W.; Fuchs, Edward J.; Gaydos, Charlotte A.; Weld, Ethel D.; Ensign, Laura M.

In: Frontiers in Cellular and Infection Microbiology, Vol. 9, No. AUG, 306, 01.01.2019.

Research output: Contribution to journalArticle

@article{904f219d470341409887f7458c17a59c,
title = "Conceptual design of a universal donor screening approach for vaginal microbiota transplant",
abstract = "The success of fecal microbiota transplant (FMT) in treating recurrent Clostridioides difficile infection has led to growing excitement about the potential of using transplanted human material as a therapy for a wide range of diseases and conditions related to microbial dysbiosis. We anticipate that the next frontier of microbiota transplantation will be vaginal microbiota transplant (VMT). The composition of the vaginal microbiota has broad impact on sexual and reproductive health. The vaginal microbiota in the “optimal” state are one of the simplest communities, dominated by one of only a few species of Lactobacillus. Diversity in the microbiota and the concomitant depletion of lactobacilli, a condition referred to as bacterial vaginosis (BV), is associated with a wide range of deleterious effects, including increased risk of acquiring sexually transmitted infections and increased likelihood of having a preterm birth. However, we have very few treatment options available, and none of them curative or restorative, for “resetting” the vaginal microbiota to a more protective state. In order to test the hypothesis that VMT may be a more effective treatment option, we must first determine how to screen donors to find those with minimal risk of pathogen transmission and “optimal” vaginal microbiota for transplant. Here, we describe a universal donor screening approach that was implemented in a small pilot study of 20 women. We further characterized key physicochemical properties of donor cervicovaginal secretions (CVS) and the corresponding composition of the vaginal microbiota to delineate criteria for inclusion/exclusion. We anticipate that the framework described here will help accelerate clinical studies of VMT.",
keywords = "Bacterial vaginosis (BV), Cervicovaginal secretions (CVS), Fecal microbiota transplant (FMT), Lactobacillus, Microbiota, Sexually transmitted infections, Urinary tract infection (UTI)",
author = "Kevin Delong and Sabrine Bensouda and Fareeha Zulfiqar and Zierden, {Hannah C.} and Hoang, {Thuy M.} and Abraham, {Alison G.} and Coleman, {Jenell S.} and Cone, {Richard A.} and Gravitt, {Patti E.} and Hendrix, {Craig W.} and Fuchs, {Edward J.} and Gaydos, {Charlotte A.} and Weld, {Ethel D.} and Ensign, {Laura M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fcimb.2019.00306",
language = "English (US)",
volume = "9",
journal = "Frontiers in cellular and infection microbiology",
issn = "2235-2988",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Conceptual design of a universal donor screening approach for vaginal microbiota transplant

AU - Delong, Kevin

AU - Bensouda, Sabrine

AU - Zulfiqar, Fareeha

AU - Zierden, Hannah C.

AU - Hoang, Thuy M.

AU - Abraham, Alison G.

AU - Coleman, Jenell S.

AU - Cone, Richard A.

AU - Gravitt, Patti E.

AU - Hendrix, Craig W.

AU - Fuchs, Edward J.

AU - Gaydos, Charlotte A.

AU - Weld, Ethel D.

AU - Ensign, Laura M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The success of fecal microbiota transplant (FMT) in treating recurrent Clostridioides difficile infection has led to growing excitement about the potential of using transplanted human material as a therapy for a wide range of diseases and conditions related to microbial dysbiosis. We anticipate that the next frontier of microbiota transplantation will be vaginal microbiota transplant (VMT). The composition of the vaginal microbiota has broad impact on sexual and reproductive health. The vaginal microbiota in the “optimal” state are one of the simplest communities, dominated by one of only a few species of Lactobacillus. Diversity in the microbiota and the concomitant depletion of lactobacilli, a condition referred to as bacterial vaginosis (BV), is associated with a wide range of deleterious effects, including increased risk of acquiring sexually transmitted infections and increased likelihood of having a preterm birth. However, we have very few treatment options available, and none of them curative or restorative, for “resetting” the vaginal microbiota to a more protective state. In order to test the hypothesis that VMT may be a more effective treatment option, we must first determine how to screen donors to find those with minimal risk of pathogen transmission and “optimal” vaginal microbiota for transplant. Here, we describe a universal donor screening approach that was implemented in a small pilot study of 20 women. We further characterized key physicochemical properties of donor cervicovaginal secretions (CVS) and the corresponding composition of the vaginal microbiota to delineate criteria for inclusion/exclusion. We anticipate that the framework described here will help accelerate clinical studies of VMT.

AB - The success of fecal microbiota transplant (FMT) in treating recurrent Clostridioides difficile infection has led to growing excitement about the potential of using transplanted human material as a therapy for a wide range of diseases and conditions related to microbial dysbiosis. We anticipate that the next frontier of microbiota transplantation will be vaginal microbiota transplant (VMT). The composition of the vaginal microbiota has broad impact on sexual and reproductive health. The vaginal microbiota in the “optimal” state are one of the simplest communities, dominated by one of only a few species of Lactobacillus. Diversity in the microbiota and the concomitant depletion of lactobacilli, a condition referred to as bacterial vaginosis (BV), is associated with a wide range of deleterious effects, including increased risk of acquiring sexually transmitted infections and increased likelihood of having a preterm birth. However, we have very few treatment options available, and none of them curative or restorative, for “resetting” the vaginal microbiota to a more protective state. In order to test the hypothesis that VMT may be a more effective treatment option, we must first determine how to screen donors to find those with minimal risk of pathogen transmission and “optimal” vaginal microbiota for transplant. Here, we describe a universal donor screening approach that was implemented in a small pilot study of 20 women. We further characterized key physicochemical properties of donor cervicovaginal secretions (CVS) and the corresponding composition of the vaginal microbiota to delineate criteria for inclusion/exclusion. We anticipate that the framework described here will help accelerate clinical studies of VMT.

KW - Bacterial vaginosis (BV)

KW - Cervicovaginal secretions (CVS)

KW - Fecal microbiota transplant (FMT)

KW - Lactobacillus

KW - Microbiota

KW - Sexually transmitted infections

KW - Urinary tract infection (UTI)

UR - http://www.scopus.com/inward/record.url?scp=85072680347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072680347&partnerID=8YFLogxK

U2 - 10.3389/fcimb.2019.00306

DO - 10.3389/fcimb.2019.00306

M3 - Article

C2 - 31555606

AN - SCOPUS:85072680347

VL - 9

JO - Frontiers in cellular and infection microbiology

JF - Frontiers in cellular and infection microbiology

SN - 2235-2988

IS - AUG

M1 - 306

ER -